Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (168)	12/8/1998 3:53:00 PM
From: nigel bates	Respond to of 1475

Rick, I know, it can make you sick being too far ahead of the market. If I had more cash I'd be a lot happier about the opportunities to accumulate. Still, keep posting & you might make the hot topics page today. nig

To: scaram(o)uche who wrote (168)	12/8/1998 7:52:00 PM
From: Larry Liebman	Read Replies (1) \| Respond to of 1475

Richard, interesting, I have positions in OSIP and CRGN. I thought I was clever purchasing OSIP at $4!!! Time will out. BTW, I spoke with IR at OSIP. All of his options are "underwater"(re:worthless), so I guess it could be substantially worse for us. He offered that Amerindo has been selling a significant number of shares over the past 3 months, continuing to pressure the price. According to him all OSIP programs are in place. He believes that if Amerindo were not selling, the price should conservatively approach its' offering price of $9. From the discussion it sounds as if PFE has placed their cancer franchise on OSIP's shoulders. Apparently, the OSIP/PFE collaboration has been going on for 13 years, with a number of pre-clinical candidates moving forward. As with BTRN, this is a company to own at these levels.